At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 6 enrolled
Drug / intervention
89Zr-TLX250drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open-label, Feasibility Study to Assess safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)
In Brief
A Early Phase 1 clinical trial evaluating 89Zr-TLX250 for Bladder Cancer. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the imaging of Non-muscle-invasive bladder cancer (NMIBC) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesFrance
CollaboratorsATONCO
Timeline
Early Ph 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartDec 2021
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMay 24, 2021
Enrollment StartDec 15, 2021
Primary CompletionAug 24, 2022
Study CompletionSep 26, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.1 years ago
Interventions
89Zr-TLX250drug
89Zr-TLX250 (89Zr-girentuximab) PET/CT performed for all aptients